Nvidia Sold Every Arm Share, but Its Vera CPU Still Uses Arm. Is That Really a Contradiction?
Yahoo Finance ·
Nvidia Sold Every Arm Share, but Its Vera CPU Still Uses Arm. Is That Really a Contradiction? Habib Ur Rehman Thu, September 3, 2026 at 3:38 PM EDT 3 min read NVDA ARM Nvidia's portfolio and product roadmap appear to be sending opposite messages about Arm. NVIDIA Corporation (NASDAQ: NVDA ) disclosed that it sold its entire position in Arm Holdings plc (NASDAQ: ARM ) by the end of 2025. Yet Nvidia's Grace CPU uses the Arm architecture, and its Vera processor does too. The apparent contradiction disappears once investors separate owning a technology licensor's stock from licensing its architecture. Nvidia can remain a major Arm customer without deciding Arm shares offer the best return. NVIDIA Corporation (NASDAQ:NVDA) benefits from architectural flexibility. Arm-based CPUs can deliver power efficiency and tight integration with Nvidia accelerators, helping the company sell complete AI systems. Exiting the equity stake also frees capital and removes a financial position that is not required for technical cooperation. The bear case is that Nvidia's growing systems ambitions make it dependent on intellectual property controlled by another company, even if licensing arrangements remain stable. Arm Holdings plc (NASDAQ:ARM) gains validation whenever Nvidia builds a flagship processor on its instruction set. AI servers expand Arm beyond smartphones, while royalties can rise as customers adopt more advanced designs. However, Arm's valuation assumes substantial growth, and licensees have incentives to negotiate hard, customize heavily, or explore alternatives. Nvidia's sale does not prove weakness, but it removes a prominent shareholder just as investors debate how much future AI success is already reflected in the stock. The cleaner interpretation is strategic independence. Nvidia appears to value Arm's technology while treating Arm's equity as a separate capital-allocation decision. That distinction is healthy for both companies: Arm can license broadly, and Nvidia can choose architectures without needing corporate ownership. Still, investors must watch royalty economics and the possibility that customers eventually seek open or internally controlled designs. Vera's adoption cadence and licensing disclosures will provide the next meaningful evidence for investors. Hedge-fund participation increased in each stock despite Nvidia's exit. Nvidia ownership rose to 285 funds in the second quarter from 275, while Arm ownership increased to 52 funds from 46. Fisher Asset Management raised its Nvidia position 3% to 90.9 million shares, while an SEC-derived filing reconstruction shows Altimeter Capital trimming Arm 4% to about 1.64 million shares. As of August 14, 18.3 million Arm shares were sold short, 1.71% of the float and 4.1 days of average volume. That longer days-to-cover figure points to more potential trading friction if shorts cover, but the product roadmap remains clear: Nvidia sold the stock, not the architecture. While we acknowledge the potential of NVDA and ARM as investments, we believe certain other AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock . READ NEXT: NVIDIA (NVDA): What Foxconn and Super Micro Are Telling Us about the AI Boom and Pony AI Is Scaling Robotaxis Fast—Can the Stock Reach BofA's $17 Target? Disclosure: None. Follow Insider Monkey on Google News .
DYAX Investor Sentiment
Bullish (Long) 43% · Bearish (Short) 57%
508 participants
Related News
- Nvidia's Jensen Huang is 'playing both sides' of AI with Hugging Face purchase
- Micron, Nvidia, and the September Effect: What 98 Years of Data Say Investors Should Do
- CLS Stock Jumps 12% As Broadcom AI Call Sparks Switch Rally
- The Gap Between HD Stock And Its Own Numbers
- Adobe (ADBE) announces Anil Chakravarthy to become President and CEO and Shantanu Narayen to become Executive Chair on December 1, 2026
- IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
